Posted in | News | Medical Robotics

Medrobotics’ Robot-Assisted Flexible Endoscopic Platform Receives CE mark

Medrobotics Corp., a medical robotics company, announced today that the Company received the CE mark for the Flex® System and will initiate a limited commercial launch of the product in select European markets.

"The Flex® System is the first robot-assisted flexible endoscopic platform for use during surgical procedures," said Samuel Straface, Ph.D., president and CEO of Medrobotics. “The system enables surgeons to access and visualize hard-to-reach anatomical locations and deploy specially designed flexible surgical instruments to perform procedures."

The Flex® System enables surgical procedures where conventional line-of-sight technologies are either not feasible or sub-optimal. Surgeons can navigate the Flex® Endoscope around anatomical structures to hard-to-reach locations through a single access site, then use the onboard high-definition vision system to precisely deploy a range of third party flexible surgical instruments. The uniquely “wristed” 3mm Flex® Instruments enable the surgeon to operate in confined spaces, further extending his or her reach to important and often challenging areas of the anatomy.

"The Flex® System provides a unique platform to access and visualize surgical targets in difficult to reach locations such as the oropharynx and endolarynx,” commented Dr. Marshall Strome, Professor and Chairman Emeritus, Cleveland Clinic Head and Neck Institute and Co-Chair of Medrobotics Medical Advisory Board. “With currently available technologies, we are often trading off between access, visualization and two-handed surgery, but the Flex® System gives us all three,” added Strome.

Minimally invasive surgery has demonstrated advantages for patients and providers compared to traditional open procedures, decreasing hospital stays and recovery times. The Flex® System was designed to provide a cost-effective, easy-to-use robot-assisted surgical platform for hospitals and surgeons seeking to provide minimally-invasive treatment options to the broadest number of patients.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.